Six biomarkers (HOTAIR, ISM2, KRTAP3-1, SPDYC, LY6G6F, and NKD1) found no drug available in LINCS1000 (Subramanian et al., 2017) to modulate their expression, and these constitute potential novel targets for drug discovery against metastatic transition in CRC. This evidence concerns the gene KRTAP3-1 and colorectal carcinoma.